Equities

IR-Med Inc

IRME:QBB

IR-Med Inc

Actions
  • Price (USD)0.67
  • Today's Change0.018 / 2.68%
  • Shares traded100.00
  • 1 Year change-39.09%
  • Beta1.0174
Data delayed at least 15 minutes, as of Jul 26 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IR-Med, Inc. is a development-stage medical device company. The Company is engaged in developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company has three principal medical devices in development. Its product under development, PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue. DiaSafe is a handheld optical monitoring device that is being developed to support early detection of DFUs in lower limb skin and underlying tissue. Nobiotics is an otoscope designed to support physicians with an immediate indication as to whether a mid-ear infection (otitis media) is of a bacterial origin.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.22m
  • Incorporated2007
  • Employees6.00
  • Location
    IR-Med IncC/O ABOUDI LEGAL GROUP PLLC745 5TH AVE, SUITE 500NEW YORK 10151United StatesUSA
  • Phone+1 (646) 768-4285
  • Fax+1 (916) 720-0663
  • Websitehttps://www.ir-medical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SeaStar Medical Holding Corp0.00-33.67m36.69m12.00---------26.64-26.640.00-1.480.00----0.00-605.20-----------------4.39---------115.19------
Movano Inc852.00k-27.91m37.73m30.00------44.29-0.5593-0.55930.0168-0.02630.0779--2.1228,400.00-254.99-151.50-559.26-188.58-42.61---3,275.47--0.5147----------3.45--4.24--
Precision Optics Corporation Inc19.41m-1.64m38.54m84.00--3.42--1.99-0.2706-0.27063.241.861.064.304.51231,098.50-8.98-6.71-13.18-10.5533.6533.65-8.43-5.021.05-8.860.1982--34.2339.1284.42--19.39--
electroCore, Inc.18.69m-16.47m38.87m68.00--8.06--2.08-2.85-2.853.130.74861.161.3054.34274,897.10-102.35-70.73-177.94-88.9682.7075.81-88.12-352.821.18--0.00--86.5774.4215.02---5.88--
Owlet Inc58.02m-23.69m39.90m76.00------0.6877-2.87-2.876.71-2.421.062.944.30763,473.70-32.36---181.41--43.05---30.61--0.8182-43.37-----21.95--52.74------
Envoy Medical Inc297.00k-22.43m41.94m34.00------141.23-2.21-2.210.0194-0.37820.04940.47372.368,735.29-381.38---2,885.46---118.18---7,718.86--0.8969-16.54----33.33---87.83------
BioNano Genomics Inc37.47m-226.79m43.41m344.00--0.4359--1.16-6.15-6.150.9421.440.16651.034.97108,924.40-100.76-56.82-128.31-67.8327.5425.38-605.26-505.761.13-83.420.0444--29.9024.65-75.34--38.51--
United Health Products Inc0.00-1.93m45.25m6.00---------0.008-0.0080.00-0.00730.000.00--0.00-719.43-6,446.86------53.19---132,561.200.0483-15.60-----100.00---55.45------
Lucid Diagnostics Inc2.98m-54.53m45.79m70.00------15.35-1.27-1.270.06980.25440.0735--78.5042,614.29-115.88---248.82---111.06---1,576.63--1.36--0.5579--544.03--6.24------
Vicarious Surgical Inc0.00-61.15m46.04m131.00--2.31-----11.78-11.780.003.380.00----0.00-54.03---56.98--------------0.00-------1,478.15------
Apyx Medical Corp50.45m-22.81m46.42m252.00--2.29--0.9202-0.6583-0.65831.460.58460.79141.774.49200,202.40-35.94-25.24-46.73-29.9763.7066.11-45.41-46.004.94-9.210.6207--17.6125.8219.28--7.99--
Vaso Corp80.54m3.18m47.32m300.0013.041.8511.570.58750.02070.02070.45890.14591.1620.037.77268,470.004.577.607.4416.6261.8358.393.955.821.37--0.0091--2.181.84-57.46---22.33--
IR-Med Inc0.00-4.22m47.36m6.00---------0.0608-0.06080.00-0.00120.00----0.00-285.64---463.30--------------2.16-------3.70------
Modular Medical Inc0.00-17.47m49.46m39.00--4.28-----0.795-0.7950.000.35530.00----0.00-165.97-187.51-187.67-234.72------------0.00-------25.87--85.63--
Cytosorbents Corp36.69m-27.54m55.94m186.00--2.95--1.52-0.5869-0.58690.77480.34860.70194.825.97197,237.50-52.69-36.00-68.27-43.5264.0868.15-75.07-62.711.21-114.700.1896--4.7910.0613.12---9.24--
Neuronetics Inc73.23m-27.54m56.70m202.00--2.05--0.7743-0.9484-0.94842.520.92260.70612.265.43360,714.30-26.56-28.02-30.98-34.7375.5275.73-37.61-51.045.18-4.270.6825--9.426.2218.76--18.57--
Data as of Jul 26 2024. Currency figures normalised to IR-Med Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.